Mineralys Therapeutics (MLYS) Expected to Release Earnings on Wednesday

Key Points

• Mineralys Therapeutics is expected to report Q3 2026 results after market close on November 4, with analysts forecasting a loss of $0.5548 per share. The company previously reported a $2.85-per-share loss, significantly missing consensus.
• MLYS shares opened at $21.24, near the lower end of their 12-month range of $20.12 to $47.65, and remain below both their 50-day and 200-day moving averages.
• Analyst sentiment is mixed, resulting in a consensus “Hold” rating and an average price target of $45.50. Insiders have sold 199,365 shares worth approximately $5.46 million over the past 90 days.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.5548) per share for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($2.30). On average, analysts expect Mineralys Therapeutics to post ($4.45) EPS for the current fiscal year and ($1.92) EPS for the next fiscal year.

Mineralys Therapeutics Stock Down 0.7%

Shares of MLYS stock opened at $21.24 on Friday. The stock's 50 day simple moving average is $24.93 and its 200 day simple moving average is $27.10. The company has a debt-to-equity ratio of 0.18, a quick ratio of 34.46 and a current ratio of 34.46. Mineralys Therapeutics has a twelve month low of $20.12 and a twelve month high of $47.65. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -5.01 and a beta of 0.69.

Insider Activity

In other Mineralys Therapeutics news, CEO Jon Congleton sold 75,000 shares of Mineralys Therapeutics stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $25.46, for a total value of $1,909,500.00. Following the transaction, the chief executive officer directly owned 528,621 shares of the company's stock, valued at $13,458,690.66. The trade was a 12.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 7,438 shares of the company's stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $28.12, for a total value of $209,156.56. Following the transaction, the insider owned 38,400 shares of the company's stock, valued at approximately $1,079,808. This trade represents a 16.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 199,365 shares of company stock worth $5,461,854 over the last 90 days. Company insiders own 18.94% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Thursday, October 15th. Zacks Research raised shares of Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Friday, September 11th. UBS Group started coverage on shares of Mineralys Therapeutics in a research note on Sunday, October 11th. They issued a "neutral" rating and a $29.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $56.00 price objective on shares of Mineralys Therapeutics in a report on Monday, October 12th. Finally, Wall Street Zen lowered shares of Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $45.50.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney diseases associated with excess aldosterone activity. The company's research centers on selectively targeting aldosterone production, a mechanism involved in blood-pressure regulation and organ damage.

Mineralys' lead product candidate is lorundrostat, an oral, selective aldosterone synthase inhibitor being evaluated as a potential treatment for uncontrolled and resistant hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.